Key result
Impaired left ventricular global longitudinal strain was significantly associated with an increased risk of major adverse cardiovascular events in patients with hypertrophic cardiomyopathy (adjusted HR 1.12; 95% CI 1.08-1.16; p<0.05).
Why the study?
Impaired left ventricular global longitudinal strain is associated with myocardial fibrosis, arrhythmias, and heart failure in hypertrophic cardiomyopathy, but its association with major adverse cardiovascular events required pooled estimation.
Is impaired left ventricular global longitudinal strain associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy?
Population
2441 HCM patients across 13 studies
Comparison
MACE vs non-MACE groups, evaluated by echocardiographic LVGLS
Design
Systematic review and meta-analysis
Authors
Loading...
Supports LVGLS for MACE risk stratification in HCM; hypothesis-generating and requires prospective validation before practice change.
Meta-Analysis (n=2,441)
Is impaired left ventricular global longitudinal strain associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy?
Hazard Ratio: 1.12 (95% CI 1.08–1.16)
p-value: p=<.05
Impaired left ventricular global longitudinal strain measured by echocardiography is a significant predictor of major adverse cardiovascular events in patients with hypertrophic cardiomyopathy.
Yang et al. (2022) conducted a meta-analysis in Hypertrophic cardiomyopathy (n=2,441). Impaired left ventricular global longitudinal strain (LVGLS) was evaluated on Major adverse cardiovascular events (MACE) (HR 1.12, 95% CI 1.08-1.16, p=<.05). Impaired left ventricular global longitudinal strain was significantly associated with an increased risk of major adverse cardiovascular events in patients with hypertrophic cardiomyopathy (adjusted HR 1.12; 95% CI 1.08-1.16; p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: